Cellectis S.A. (CLLS) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cellectis S.A. (CLLS) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 80.4% versus a loss of 80.4%. Over five years, CLLS leads with a -89.4% price change compared with -98.7% for NBP. NovaBridge Biosciences is the larger company by market cap ($96.3 million vs $92.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | NBP |
|---|---|---|
| Share price | $0.9209 | $0.83 |
| Market cap | $92.76M | $96.28M |
| 1-day change | -7.89% | -5.66% |
| YTD return | -80.97% | -79.15% |
| 1-year return | -80.36% | -80.38% |
| 5-year return | -89.40% | -98.69% |
| EPS (TTM) | $-1.26 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.95M | — |
| Revenue growth (YoY) | +75.76% | — |
| Net income (latest FY) | $-67.59M | $-46.27M |
| Gross margin | 100.00% | — |
| Operating margin | -45.34% | — |
| Net margin | -92.66% | — |
| 52-week high | $5.45 | $5.19 |
| 52-week low | $0.881 | $0.751 |
| Distance from 52-week high | -83.10% | -84.01% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +497.24% | +944.58% |
| Average volume | 115.00K | 515.66K |
| Shares outstanding | 72.73M | 116.00M |
| Employees | 224 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
CLLS vs NBP FAQ
Which is bigger, Cellectis S.A. or NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $96.28M compared with $92.76M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, CLLS or NBP?
CLLS returned -80.36% over the past 12 months, compared with -80.38% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.